Longeveron Inc. (LGVN)
LGVN Stock Price Chart
Explore Longeveron Inc. interactive price chart. Choose custom timeframes to analyze LGVN price movements and trends.
LGVN Company Profile
Discover essential business fundamentals and corporate details for Longeveron Inc. (LGVN) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
12 Feb 2021
Employees
25.00
Website
https://www.longeveron.comCEO
Stephen H. Willard
Description
Longeveron Inc. is a biotechnology company currently in the clinical development stage, dedicated to pioneering cell-based therapies. These treatments are designed to address both age-related conditions and various critical, life-threatening illnesses. The company's primary investigational product is LOMECEL-B, a sophisticated cellular therapy. This product is created from medicinal signaling cells that are cultivated and expanded after being harvested from the bone marrow of healthy young adult donors. Longeveron is actively conducting Phase 1 and Phase 2 clinical trials to evaluate LOMECEL-B's potential across a diverse range of indications. These include age-related frailty, Alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). Established in 2014, Longeveron Inc. operates from its headquarters in Miami, Florida.
LGVN Financial Timeline
Browse a chronological timeline of Longeveron Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 12 Aug 2026
EPS estimate is -$0.19, while revenue estimate is $326.00k.
Earnings released on 13 May 2026
EPS came in at -$0.19 matching the estimated -$0.19, while revenue for the quarter reached $398.00k , beating expectations by +18.98%.
Earnings released on 17 Mar 2026
EPS came in at -$0.22 surpassing the estimated -$0.42 by +47.62%, while revenue for the quarter reached $365.00k , beating expectations by +230.82%.
Earnings released on 4 Nov 2025
EPS came in at -$0.39 falling short of the estimated -$0.26 by -50.00%, while revenue for the quarter reached $137.00k , beating expectations by +24.17%.
Earnings released on 13 Aug 2025
EPS came in at -$0.33 surpassing the estimated -$0.35 by +5.71%, while revenue for the quarter reached $316.00k , missing expectations by -28.83%.
Earnings released on 8 May 2025
EPS came in at -$0.34 matching the estimated -$0.34, while revenue for the quarter reached $381.00k , missing expectations by -35.71%.
Earnings released on 28 Feb 2025
EPS came in at -$2.50 falling short of the estimated -$0.36 by -594.44%, while revenue for the quarter reached $603.00k , beating expectations by +4.21%.
Earnings released on 12 Nov 2024
EPS came in at -$0.34 surpassing the estimated -$0.53 by +35.85%, while revenue for the quarter reached $773.00k , beating expectations by +95.45%.
Earnings released on 14 Aug 2024
EPS came in at -$1.83 falling short of the estimated -$1.03 by -77.67%, while revenue for the quarter reached $468.00k , missing expectations by -6.40%.
Earnings released on 14 May 2024
EPS came in at -$1.61 surpassing the estimated -$2.01 by +19.90%, while revenue for the quarter reached $548.00k , beating expectations by +813.33%.
Stock split effective on 27 Mar 2024
Shares were split 1 : 10 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 27 Feb 2024
EPS came in at -$2.50 falling short of the estimated -$2.10 by -19.05%, while revenue for the quarter reached $63.00k , missing expectations by -70.00%.
Earnings released on 10 Nov 2023
EPS came in at -$2.80 falling short of the estimated -$2.40 by -16.67%, while revenue for the quarter reached $150.00k , missing expectations by -62.50%.
Earnings released on 11 Aug 2023
EPS came in at -$2.70 falling short of the estimated -$2.60 by -3.85%, while revenue for the quarter reached $217.00k , missing expectations by -45.75%.
Earnings released on 12 May 2023
EPS came in at -$2.20 falling short of the estimated -$1.90 by -15.79%, while revenue for the quarter reached $279.00k , missing expectations by -7.00%.
Earnings released on 10 Mar 2023
EPS came in at -$2.10 falling short of the estimated -$1.00 by -110.00%, while revenue for the quarter reached $121.00k , missing expectations by -69.75%.
Earnings released on 14 Nov 2022
EPS came in at -$2.50 falling short of the estimated -$2.00 by -25.00%, while revenue for the quarter reached $265.00k , beating expectations by +32.50%.
Earnings released on 12 Aug 2022
EPS came in at -$2.70 falling short of the estimated -$2.30 by -17.39%, while revenue for the quarter reached $466.00k , beating expectations by +133.00%.
Earnings released on 13 May 2022
EPS came in at -$1.70 surpassing the estimated -$2.10 by +19.05%, while revenue for the quarter reached $370.00k , beating expectations by +48.00%.
Earnings released on 11 Mar 2022
EPS came in at -$2.00 surpassing the estimated -$2.50 by +20.00%, while revenue for the quarter reached $209.00k , missing expectations by -21.13%.
Earnings released on 12 Nov 2021
EPS came in at -$2.50 , while revenue for the quarter reached $232.00k .
Earnings released on 13 Aug 2021
EPS came in at -$2.60 , while revenue for the quarter reached $489.00k .
LGVN Stock Performance
Access detailed LGVN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
